Known targets — ChEMBL curated mechanism
ABL1BCRBLKEPHA2FGRFRKFYNHCKKITLCKLYNPDGFRBSRCSRMSYES1
The experimentally established mechanism targets of Dasatinib Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 known ✓ | P00519 | 10/20 | 1.00 |
| ▸ | SRC known ✓ | P12931 | 5/20 | 1.00 |
| ▸ | LCK known ✓ | P06239 | 4/20 | 1.00 |
| ▸ | FYN known ✓ | P06241 | 2/20 | 1.00 |
| ▸ | YES1 known ✓ | P07947 | 2/20 | 1.00 |
| ▸ | LYN known ✓ | P07948 | 2/20 | 1.00 |
| ▸ | HCK known ✓ | P08631 | 2/20 | 1.00 |
| ▸ | KIT known ✓ | P10721 | 2/20 | 1.00 |
| ▸ | BCR known ✓ | P11274 | 2/20 | 1.00 |
| ▸ | EPHA2 known ✓ | P29317 | 2/20 | 1.00 |
| ▸ | FRK known ✓ | P42685 | 2/20 | 1.00 |
| ▸ | PDGFRB known ✓ | P09619 | 1/20 | 1.00 |
| ▸ | FGR known ✓ | P09769 | 1/20 | 1.00 |
| ▸ | BLK known ✓ | P51451 | 1/20 | 1.00 |
| ▸ | SRMS known ✓ | Q9H3Y6 | 1/20 | 1.00 |
| ▸ | SIK2 | Q9H0K1 | 8/20 | 1.00 |
| ▸ | SIK3 | Q9Y2K2 | 8/20 | 1.00 |
| ▸ | SIK1 | P57059 | 6/20 | 1.00 |
| ▸ | PKMYT1 | Q99640 | 3/20 | 1.00 |
| ▸ | EPHB6 | O15197 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dasatinib Anhydrous SCHEMBL16618224 | 1.00 | ABL1 (1.00) | ABL1SIK2SIK3SIK1SRC | |
| Dasatinib Anhydrous SCHEMBL29377489 | 1.00 | ABL1 (1.00) | ABL1SIK2SIK3SIK1SRC | |
| Dasatinib Anhydrous SCHEMBL16618598 | 1.00 | ABL1 (1.00) | ABL1SIK2SIK3SIK1SRC | |
| Dasatinib Anhydrous SCHEMBL29482416 | 1.00 | ABL1 (1.00) | ABL1SIK2SIK3SIK1SRC | |
| Dasatinib Anhydrous SCHEMBL16913911 | 0.99 | ABL1 (0.98) | ABL1SIK2SIK3SIK1SRC | |
| Dasatinib Anhydrous SCHEMBL29381185 | 0.99 | ABL1 (1.00) | ABL1SIK2SIK3SIK1SRC | |
| Dasatinib Anhydrous SCHEMBL8226 | 0.99 | ABL1 (1.00) | ABL1SIK2SIK3SIK1SRC | |
| Dasatinib Anhydrous SCHEMBL28350326 | 0.99 | ABL1 (1.00) | ABL1SIK2SIK3SIK1SRC | |
| Dasatinib Anhydrous SCHEMBL20857008 | 0.98 | ABL1 (0.98) | ABL1SIK2SIK3SIK1SRC | |
| Dasatinib Anhydrous SCHEMBL1705152 | 0.98 | ABL1 (0.98) | ABL1SIK2SIK3SIK1SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 673 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026043541-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | TUFTS MEDICAL CENTER, INC. (US) | 2026-02-26 | — | — | WO | claimed |
| US-20250312349-A1 | COMPOSITION AND METHODS OF TREATING INTRACELLULAR PATHOGEN INFECTION | UNIV HOSPITALS CLEVELAND MEDICAL CENTER (US) | 2025-10-09 | — | — | US | claimed |
| US-20250297310-A1 | HEMATOPOIETIC LOSS OF Y CHROMOSOME LEADS TO CARDIAC FIBROSIS AND DYSFUNCTION AND IS ASSOCIATED WITH DEATH DUE TO HEART FAILURE | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2025-09-25 | — | — | US | claimed |
| US-12144804-B1 | Pharmaceutical compositions | XSPRAY PHARMA AB (SE) | 2024-11-19 | — | — | US | claimed |
| US-20240374577-A1 | PHARMACEUTICAL COMPOSITIONS | XSPRAY PHARMA AB (SE) | 2024-11-14 | — | — | US | claimed |
| US-12076314-B2 | Pharmaceutical compositions | XSPRAY PHARMA AB (SE) | 2024-09-03 | — | — | US | claimed |
| US-20240189290-A1 | PHARMACEUTICAL COMPOSITIONS | XSPRAY PHARMA AB (SE) | 2024-06-13 | — | — | US | claimed |
| WO-2023183822-A1 | HEMATOPOIETIC LOSS OF Y CHROMOSOME LEADS TO CARDIAC FIBROSIS AND DYSFUNCTION AND IS ASSOCIATED WITH DEATH DUE TO HEART FAILURE | UNIVERSITY OF VIRGINA PATENT FOUNDATION (US) | 2023-09-28 | — | — | WO | claimed |
| US-11723891-B2 | Drug combinations for use in the treatment of RAS-mutant cancer | UMC UTRECHT HOLDING B.V. (NL) | 2023-08-15 | — | — | US | claimed |
| CN-110862387-B | Novel dasatinib crystal form and preparation method thereof | 鲁南制药集团股份有限公司 | 2023-05-16 | — | — | CN | claimed |
| EP-2535339-A1 | POLYMORPHS OF DASATINIB, PREPARATION METHODS AND PHARMACEUTICAL COMPOSITIONS THEREOF | Nanjing Cavendish Bio-Engineering Technology Co., Ltd. (CN) | 2012-12-19 | — | — | EP | claimed |
| US-20120309968-A1 | POLYMORPHS OF DASATINIB, PREPARATION METHODS AND PHARMACEUTICAL COMPOSITIONS THEREOF | NAN JING CAVENDISH BIO-ENGINEERING TECHNOLOGY CO., LTD. (CN) | 2012-12-06 | — | — | US | claimed |
| CN-101891738-B | Dasatinib polymorphic substance, preparation method and medicinal composition thereof | NANJING CAVENDISH BIOENGINEERING TECHNOLOGY CO LTD | 2011-09-28 | — | — | CN | claimed |
| CN-102086195-A | Dasatinib polymorphic substance as well as preparation method and medicinal composition thereof | NANJING CAVENDISH BIO ENGINEERING TECHNOLOGY CO LTD | 2011-06-08 | — | — | CN | claimed |
| WO-2010139980-A1 | PROCESS FOR PREPARING CRYSTALLINE DASATINIB MONOHYDRATE | GENERICS [UK] LIMITED (GB) | 2010-12-09 | — | — | WO | claimed |
| WO-2010139979-A2 | PROCESSES FOR PREPARING CRYSTALLINE FORMS | GENERICS [UK] LIMITED (GB) | 2010-12-09 | — | — | WO | claimed |
| WO-2010139981-A2 | PROCESSES FOR PREPARING CRYSTALLINE FORMS | GENERICS [UK] LIMITED (GB) | 2010-12-09 | — | — | WO | claimed |
| CN-101891738-A | Dasatinib polymorphic substance, preparation method and medicinal composition thereof | NANJING CAVENDISH BIO ENGINEERING TECHNOLOGY CO LTD | 2010-11-24 | — | — | CN | claimed |
| WO-2010067374-A2 | POLYMORPHS OF DASATINIB | HETERO RESEARCH FOUNDATION (IN) | 2010-06-17 | — | — | WO | claimed |
| US-20100069340-A1 | PHARMACEUTICAL COMPOSITIONS OF AN SRC KINASE INHIBITOR AND AN AROMATASE INHIBITOR | WYETH (US) | 2010-03-18 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309968-A1 | POLYMORPHS OF DASATINIB, PREPARATION METHODS AND PHARMACEUTICAL COMPOSITIONS THEREOF | SRC, ABL1, NRAS | ABL1 2/4885SRC 1/4885LCK 103/4885 |
| US-20100069340-A1 | PHARMACEUTICAL COMPOSITIONS OF AN SRC KINASE INHIBITOR AND AN AROMATASE INHIBITOR | CYP19A1, SRC, CYP17A1 | ABL1 39/4885SRC 2/4885LCK 12/4885 |
| US-20250297310-A1 | HEMATOPOIETIC LOSS OF Y CHROMOSOME LEADS TO CARDIAC FIBROSIS AND DYSFUNCTION AND IS ASSOCIATED WITH DEATH DUE TO HEART FAILURE | YWHAG, MYLK2, TERF2 | ABL1 1871/4885SRC 699/4885LCK 303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.